AIM Vaccine Co Ltd Class H 06660
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$4.45
- Day Range
- HK$4.60–6.40
- 52-Week Range
- HK$3.95–34.00
- Bid/Ask
- HK$5.77 / HK$5.79
- Market Cap
- HK$6.99 Bil
- Volume/Avg
- 8.6 Mil / 358,800
Key Statistics
- Price/Earnings (Normalized)
- 11.88
- Price/Sales
- 4.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates all of its revenues in the PRC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,557
- Website
- https://www.aimbio.com
Comparables
Valuation
|
Metric
|
06660
|
300841
|
430047
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.88 | 11.04 | — |
Price/Book Value | 2.17 | 1.97 | 8.27 |
Price/Sales | 4.19 | 3.98 | 39.88 |
Price/Cash Flow | — | 9.22 | — |
Price/Earnings
06660
300841
430047
Financial Strength
|
Metric
|
06660
|
300841
|
430047
|
|---|---|---|---|
Quick Ratio | 0.67 | 4.18 | 3.53 |
Current Ratio | 0.85 | 4.57 | 3.87 |
Interest Coverage | −38.31 | 124.81 | −127.19 |
Quick Ratio
06660
300841
430047
Profitability
|
Metric
|
06660
|
300841
|
430047
|
|---|---|---|---|
Return on Assets (Normalized) | −3.14% | 15.47% | −9.36% |
Return on Equity (Normalized) | −6.94% | 18.16% | −15.90% |
Return on Invested Capital (Normalized) | −3.60% | 17.07% | −13.55% |
Return on Assets
06660
300841
430047
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hxvybbjcl | Xcv | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hgntkygd | Gmvkx | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Czdxjjsl | Gfzcy | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tkryrncr | Ntvstjj | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Tqxqygl | Jpv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Gcwljqjc | Vmprg | $28.0 Bil | |||
| Moderna Inc
MRNA
| Nrgwzwc | Pgzn | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Gdllsbm | Hqsy | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dqxvwynj | Kqjtzl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Brfqwmcmkh | Tsqcwx | $12.6 Bil |
United States